Mayer Brown Represents HDL Therapeutics in Merger With Swiftmerge Acquisition
August 12, 2023
August 12, 2023
CHICAGO, Illinois, Aug. 12 -- Mayer Brown, a law firm, issued the following news:
A Mayer Brown team represented HDL Therapeutics, Inc., a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia, in its definitive merger agreement with Swiftmerge Acquisition Corp., a special purpose acquisition company, in a transaction valued at $480 million.
The . . .
A Mayer Brown team represented HDL Therapeutics, Inc., a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia, in its definitive merger agreement with Swiftmerge Acquisition Corp., a special purpose acquisition company, in a transaction valued at $480 million.
The . . .